DNMT3B and head and neck cancer: A previous study that involved a smaller number of head and neck cancer patients evaluated survival and relapse-free time for the DNMT3B 46359C/T and SHMT1 1420C/T polymorphisms, but failed to demonstrate any statistically significant association between the wild-type and polymorphic carriers (Succi et al., 2014).